Literature DB >> 33341086

CT for detection of malignant posterior intercostal lymph nodes in patients undergoing pre-operative staging for malignant pleural mesothelioma.

I Berger1, Scott Simpson1, J S Friedberg2, Melissa J Culligan2, E Paul Wileyto1, Evan W Alley1, D Sterman3, Akash M Patel1, U Khalid1, C B Simone4, Keith A Cengel1, Sharyn I Katz5, L Roshkovan6.   

Abstract

INTRODUCTION: Recent evidence suggests that patients with malignant pleural mesothelioma (MPM) undergoing extended pleurectomy/decortication (eP/D) with metastasis to the posterior intercostal lymph nodes (PILN) have a worse prognosis. In this study, we determine if MPM PILN metastasis can be reliably detected on computed tomography (CT).
MATERIALS AND METHODS: Preoperative staging CT exams were reviewed for the presence of PILN in MPM patients undergoing eP/D between 2007-2013 with surgical sampling of their PILN. CT images were reviewed by two thoracic radiologists blinded to clinical records, including operative pathology reports. The number and short axis size of PILN were recorded and correlated with surgical pathology. Statistical analysis examined the value of preoperative CT to detect metastatic PILN.
RESULTS: Of 36 patients that underwent eP/D with PILN sampling had preoperative CT images for review. At surgery, 22 of these patients had metastatic PILN and 14 had benign PILN. The positive and negative predictive values for one or more nodes seen on preoperative CT were 60 % and 38 % respectively. The number of PILN on preoperative CT did not predict metastasis (p = 0.40) with an average of 2 PILN seen, regardless of PILN pathology. The average nodal short axis size was 4.6 mm and 4.8 mm for benign and malignant PILN, respectively, and PILN short axis size did not predict metastasis (p = 0.39). There was little inter-observer variability between the size and number of nodes detected by each radiologist.
CONCLUSIONS: CT does not reliably identify metastatic PILN on preoperative CT for patients with MPM undergoing extended pleurectomy/decortication.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CT; Mesothelioma; Posterior intercostal lymph nodes; Staging

Mesh:

Year:  2020        PMID: 33341086      PMCID: PMC7936656          DOI: 10.1016/j.lungcan.2020.12.003

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  16 in total

1.  Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.

Authors:  R T Heelan; V W Rusch; C B Begg; D M Panicek; J F Caravelli; C Eisen
Journal:  AJR Am J Roentgenol       Date:  1999-04       Impact factor: 3.959

Review 2.  The eighth TNM classification for malignant pleural mesothelioma.

Authors:  Lawek Berzenji; Paul E Van Schil; Laurens Carp
Journal:  Transl Lung Cancer Res       Date:  2018-10

3.  Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting.

Authors:  Ritu R Gill; Anne S Tsao; Hedy L Kindler; William G Richards; Samuel G Armato; Roslyn J Francis; Daniel R Gomez; Suzanne Dahlberg; Andreas Rimner; Charles B Simone; Marc de Perrot; Gideon Blumenthal; Alex A Adjei; Raphael Bueno; David H Harpole; Mary Hesdorffer; Fred R Hirsch; Harvey I Pass; Ellen Yorke; Kenneth Rosenzweig; Bryan Burt; Dean A Fennell; Wolf Lindwasser; Shakun Malik; Tobias Peikert; Aaron S Mansfield; Ravi Salgia; Haining Yang; Valerie W Rusch; Anna K Nowak
Journal:  J Thorac Oncol       Date:  2019-08-27       Impact factor: 15.609

4.  Posterior Intercostal Lymph Nodes Double Recurrence and Death Risk in Malignant Pleural Mesothelioma.

Authors:  Joseph S Friedberg; Charles B Simone; Melissa J Culligan; Mary E Putt; Andrew R Barsky; Sharyn Katz; Keith A Cengel
Journal:  Ann Thorac Surg       Date:  2019-10-18       Impact factor: 4.330

5.  A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.

Authors:  V W Rusch
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

Review 6.  A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.

Authors:  Christopher Cao; David Tian; John Park; James Allan; Kristopher A Pataky; Tristan D Yan
Journal:  Lung Cancer       Date:  2013-12-06       Impact factor: 5.705

7.  The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.

Authors:  David Rice; Kari Chansky; Anna Nowak; Harvey Pass; Hedy Kindler; Lynn Shemanski; Isabelle Opitz; Sergi Call; Seiki Hasegawa; Kemp Kernstine; Cansel Atinkaya; Federico Rea; Philippe Nafteux; Valerie W Rusch
Journal:  J Thorac Oncol       Date:  2016-09-26       Impact factor: 15.609

8.  The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma.

Authors:  Valerie W Rusch; Kari Chansky; Hedy L Kindler; Anna K Nowak; Harvey I Pass; David C Rice; Lynn Shemanski; Françoise Galateau-Sallé; Brian C McCaughan; Takashi Nakano; Enrico Ruffini; Jan P van Meerbeeck; Masahiro Yoshimura
Journal:  J Thorac Oncol       Date:  2016-09-28       Impact factor: 15.609

Review 9.  Nodal staging.

Authors:  Skandadas Ganeshalingam; Dow-Mu Koh
Journal:  Cancer Imaging       Date:  2009-12-24       Impact factor: 3.909

10.  Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.

Authors:  Martin F Muers; Richard J Stephens; Patricia Fisher; Liz Darlison; Christopher M B Higgs; Erica Lowry; Andrew G Nicholson; Mary O'Brien; Michael Peake; Robin Rudd; Michael Snee; Jeremy Steele; David J Girling; Matthew Nankivell; Cheryl Pugh; Mahesh K B Parmar
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.